August 17, 2017 5:10 AM ET

Pharmaceuticals

Company Overview of F. Hoffmann-La Roche Ltd

Company Overview

F. Hoffmann-La Roche Ltd. provides in-vitro diagnostics and drugs for cancer and transplantation. The company specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. The company also researches, develops, and produces molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostic...

Konzern-Hauptsitz

Grenzacherstrasse 124

Basel,  4070

Switzerland

Founded in 1896

Phone:

41 61 688 11 11

Fax:

41 61 691 93 91

Key Executives for F. Hoffmann-La Roche Ltd

Chief Executive Officer of Roche Group
Age: 50
Head of Roche Basel Site
Compensation as of Fiscal Year 2017.

F. Hoffmann-La Roche Ltd Key Developments

Dermira, Inc. Enters into Licensing Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc

Dermira, Inc. announced that it has entered into a licensing agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc., a member of the Roche Group (together Roche). Pursuant to the agreement, Dermira will obtain exclusive, worldwide rights to develop and commercialize lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic dermatitis and all other indications, except Roche will retain certain rights, including exclusive rights to develop and promote lebrikizumab for interstitial lung diseases, such as idiopathic pulmonary fibrosis. Under the terms of the agreement, Dermira will make an initial payment of $80 million to Roche and payments totaling $55 million in 2018. Dermira will also be obligated to make additional payments upon the achievement of certain milestones, comprising $40 million upon the initiation of Dermira’s first Phase 3 clinical study, up to $210 million upon the achievement of regulatory and first commercial sale milestones in certain territories and up to $1.025 billion based on the achievement of certain thresholds for net sales of lebrikizumab for indications other than interstitial lung disease. Upon potential regulatory approval, Dermira will make royalty payments representing percentages of net sales that range from the high single-digits to the high teens. The effectiveness of the agreement is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, as amended (HSR). The transaction is expected to close in the third quarter of 2017 subject to the expiration or termination of the waiting period under HSR.

F. Hoffmann-La Roche Ltd Presents at Pre-Filled Syringes San Diego Summit, Jun-06-2017 04:40 PM

F. Hoffmann-La Roche Ltd Presents at Pre-Filled Syringes San Diego Summit, Jun-06-2017 04:40 PM. Venue: HYATT REGENCY MISSION BAY, 1441 Quivira Road, San Diego, California, United States. Speakers: Monica De Bardi, Post Doctoral Researcher.

F. Hoffmann-La Roche Ltd Presents at BIO International Conference 2017, Jun-20-2017 11:15 AM

F. Hoffmann-La Roche Ltd Presents at BIO International Conference 2017, Jun-20-2017 11:15 AM. Venue: San Diego Convention Center, San Diego, CA 2865, United States.

Similar Private Companies By Industry

Company Name Region
Acino International AG Europe
Activen SA Europe
AL-S Pharma AG Europe
Albea Pharmaceuticals AG Europe
Alpen Pharma AG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact F. Hoffmann-La Roche Ltd, please visit www.roche.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.